These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9061299)

  • 1. Perspectives on chemoprevention agent selection and short-term clinical prevention trials.
    Kelloff GJ; Hawk ET; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
    Eur J Cancer Prev; 1996 Dec; 5 Suppl 2():79-85. PubMed ID: 9061299
    [No Abstract]   [Full Text] [Related]  

  • 2. Exisulind shows positive results in the prevention of precancerous colon polyps.
    Oncology (Williston Park); 2000 May; 14(5):772-3. PubMed ID: 10853464
    [No Abstract]   [Full Text] [Related]  

  • 3. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
    Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Fabian CJ; Kimler BF
    Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Cancer Chernoprevention: Current Status and Future Direction.
    Messadi DV; Sato K
    J Calif Dent Assoc; 2016 Feb; 44(2):101-11. PubMed ID: 26930753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous cell carcinoma and precursor lesions: prevention.
    Warnakulasuriya S
    Periodontol 2000; 2011 Oct; 57(1):38-50. PubMed ID: 21781178
    [No Abstract]   [Full Text] [Related]  

  • 9. Retinoids in chemoprevention of head and neck carcinogenesis.
    Lippman SM; Benner SE; Hong WK
    Prev Med; 1993 Sep; 22(5):693-700. PubMed ID: 8234209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counterpoint: From animal models to prevention of colon cancer. Criteria for proceeding from preclinical studies and choice of models for prevention studies.
    Bruce WR
    Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):401-4. PubMed ID: 12750233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranking chemopreventive agents on rat colon carcinogenesis.
    Corpet DE; Taché S
    IARC Sci Publ; 2002; 156():381-4. PubMed ID: 12484212
    [No Abstract]   [Full Text] [Related]  

  • 13. Fenretinide: a prototype cancer prevention drug.
    Malone W; Perloff M; Crowell J; Sigman C; Higley H
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1829-42. PubMed ID: 14585058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.
    Corpet DE; Pierre F
    Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):391-400. PubMed ID: 12750232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of oral premalignant lesions: concepts and implications for chemoprevention.
    Papadimitrakopoulou VA; Hong WK
    Eur J Cancer Prev; 1996 Dec; 5 Suppl 2():87-93. PubMed ID: 9061300
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemoprevention of cancer: review of the literature.
    Swan DK; Ford B
    Oncol Nurs Forum; 1997 May; 24(4):719-27. PubMed ID: 9159786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of lung cancer.
    Benner SE; Lippman SM; Hong WK
    Chest; 1995 Jun; 107(6 Suppl):316S-321S. PubMed ID: 7781413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck.
    Lippman SM; Spitz MR; Huber MH; Hong WK
    Curr Opin Oncol; 1995 May; 7(3):234-41. PubMed ID: 7654825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in prostate cancer chemoprevention: modulators of promotion and progression.
    Lieberman R; Bermejo C; Akaza H; Greenwald P; Fair W; Thompson I
    Urology; 2001 Dec; 58(6):835-42. PubMed ID: 11744441
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemoprevention of (pre)malignant disorders of the head and neck area. Current situation].
    de Vries N; Snow GB
    Ned Tijdschr Tandheelkd; 1994 Mar; 101(3):93-4; quiz 95, 110. PubMed ID: 11830958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.